FDG PET监测非小细胞肺癌抗PD-1免疫治疗:iPERCIST的引入
该回顾性分析纳入28例接受纳武利尤单抗治疗的NSCLC患者,于治疗前和2个月后行FDG PET,采用iPERCIST双时间点评估疗效。应答者总生存显著长于非应答者(19.9 vs 3.6个月,log rank p=0.0003),1年生存率分别为94%和11%。iPERCIST与iRECIST比较使39%(11/28)患者重新分类并获得额外预后信息。
要点
- iPERCIST双时间点评估可识别从抗PD-1治疗中获益最多的NSCLC患者。
- 应答者总生存19.9个月,非应答者3.6个月,log rank p=0.0003。
- 1年生存率应答者94%、非应答者11%。
核心结论
- iPERCIST双时间点评估可能是评估抗PD-1免疫治疗的有力工具,能识别最可能获益的患者。
- iPERCIST标准的预后价值需在大型前瞻性多中心研究中确认。
研究设计与样本
- 回顾性分析28例接受纳武利尤单抗(PD-1阻断剂)治疗的NSCLC患者。
- 所有患者治疗前行PET扫描(SCAN-1),2个月后行另一次扫描(SCAN-2)。
- 采用改编自PERCIST的iPERCIST评估疾病进展,并与iRECIST比较。
- iPERCIST为双时间点评估SCAN-2时「未确认的进展性代谢病」(UPMD)状态,UPMD在SCAN-2后4周经SCAN-3确认PMD。
- SCAN-2或SCAN-3时为完全/部分代谢缓解(CMR或PMR)或稳定代谢病(SMD)者视为应答者,SCAN-3确认UPMD者为非应答者。
主要发现
- SCAN-2时发现9/28例PMR、4/28例SMD、2/28例CMR、13/28例UPMD。
- 13例UPMD患者中4例在SCAN-3时归为应答者(PMR n=1,SMD n=3),其余9例因临床恶化归为非应答者并停止治疗。
- 中位随访16.7个月[3.6-32.2],应答者继续治疗平均10.7个月[3.8-26.3]。
- 应答者总生存长于非应答者(19.9 vs 3.6个月,log rank p=0.0003)。
- 1年生存率应答者为94%、非应答者为11%;与iRECIST比较,39%(11/28)患者被重新分类并获得相关额外预后信息。
关键数值与推荐
- iPERCIST采用双时间点评估UPMD:SCAN-2发现UPMD后4周行SCAN-3确认PMD。
- SCAN-2或SCAN-3时为CMR、PMR或SMD者判为应答者,SCAN-3确认UPMD者为非应答者。
临床怎么用
- 对接受抗PD-1治疗的NSCLC患者,可考虑FDG PET双时间点iPERCIST评估以辅助判断疗效。
- SCAN-2出现UPMD者可在4周后复查SCAN-3确认,避免过早判定进展。
- iPERCIST与iRECIST比较可提供额外预后信息,有助于识别可能获益患者。
局限性
- 本研究为回顾性分析,样本量为28例。
- iPERCIST标准的预后价值尚需大型前瞻性多中心研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunotherapy represents a new therapeutic approach in non-small cell lung carcinoma (NSCLC) with the potential for prolonged benefits. Because of the systemic nature and heterogeneity of tumoral diseases, as well as the immune restoration process induced by immunotherapy, the assessment of therapeutic efficacy is challenging, and the role of FDG PET is not well established. We evaluated the potential of FDG PET to monitor NSCLC patients treated with a checkpoint inhibitor. RESULTS: This was a retrospective analysis of 28 NSCLC patients treated with nivolumab, a programmed cell death 1 (PD-1) blocker. All patients underwent a PET scan before treatment (SCAN-1) and another scan 2 months later (SCAN-2). Disease progression was assessed by immune PET Response Criteria in Solid Tumors (iPERCIST), which was adapted from PERCIST; and the immune Response Evaluation Criteria in Solid Tumors (iRECIST). iPERCIST is a dual-time-point evaluation of "unconfirmed progressive metabolic disease" (UPMD) status at SCAN-2. UPMD at SCAN-2 was re-evaluated after 4 weeks with SCAN-3 to confirm PMD. Patients with complete/partial metabolic response (CMR or PMR) or stable metabolic disease (SMD) at SCAN-2 or -3 were considered responders. Patients with UPMD confirmed at SCAN-3 were considered non-responders. The Kaplan-Meier method was used to estimate survival. At SCAN-2, we found 9/28 cases of PMR, 4/28 cases of SMD, 2/28 cases of CMR, and 13/28 cases of UPMD. Four of the 13 UPMD patients were classified as responders at SCAN-3 (PMR n = 1, SMD n = 3). The remaining nine UPMD patients were classified as non-responders due to clinical degradation, and treatment was stopped. The median follow-up was 16.7 months [3.6-32.2]. Responders continued treatment for a mean of 10.7 months [3.8-26.3]. Overall survival was longer for responders than that for non-responders (19.9 vs. 3.6 months, log rank p = 0.0003). The 1-year survival rates were 94% for responders and 11% for non-responders. A comparison with iRECIST showed reclassification in 39% (11/28) of patients with relevant additional prognostic information. CONCLUSIONS: iPERCIST dual-time-point evaluation might be a powerful tool for evaluating anti-PD-1-based immunotherapy, with the ability to identify patients who can benefit most from treatment. The prognostic value of iPERCIST criteria should be confirmed in large prospective multicentric studies.
引用
- Goldfarb L, Duchemann B, Chouahnia K, et al. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. EJNMMI Res. 2019. PMID: 30694399. doi:10.1186/s13550-019-0473-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。